http://www.sciencedaily.com/releases/2011/02/110204142257.htm
ScienceDaily (Feb. 5, 2011) — The vaccine for human papillomavirus (HPV) can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine, according to a new multi-center study led by H. Lee Moffitt Cancer Center and UCSF.
The four-year, international clinical trial, which also found a nearly 66 percent effectiveness in the general population of young men regardless of prior exposure to these strains, provides the first reported results of using the HPV vaccine as a prophylactic in men.
Initial data from this study informed the Food and Drug Administration's decision to approve the vaccine for boys in 2009 to prevent warts, while results from a substudy led the FDA to expand approval late last year to prevent anal cancer. Findings can be found in the Feb. 3 issue of the New England Journal of Medicine.
----- (skipping)
..
No comments:
Post a Comment